OBJECTIVE: To determine the prevalence of illicit drug use and the impact on HIV treatment. DESIGN: Multivariable regression of cross-sectional data from 1163 HIV-infected and 294 controls from the Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). METHODS: An analysis of (1) prevalence of specific illicit drug use (ever, current), (2) being on HAART among those with an indication and (3) current HIV RNA and CD4 cell count among HAART users. RESULTS: Median age was 42 years, approximately 50% were non-Caucasian and 33% were women. Eighty-six percent of HIV-infected and 67% of controls reported ever using illicit drugs (P < 0.0001); 28% of HIV-infected and 16% of controls reported current use (P = 0.0001). In adjusted models, current cocaine use and past heroin use were associated with not currently being on HAART. Among HAART users, those reporting past heroin use were as likely to have an undetectable HIV viral load as those who had never used heroin. Current and past cocaine use and current heroin use was associated with lower odds of undetectable HIV RNA. Past amphetamine use was associated with having an undetectable HIV. Similar results were seen for CD4 lymphocyte counts. CONCLUSION: Illicit drug use in the US is common, although far fewer report current use than past use. Among HIV-infected patients, understanding of the type of illicit drugs used and whether drug use was in the past or ongoing is important, because of their differential effects on HIV treatment outcomes.
OBJECTIVE: To determine the prevalence of illicit drug use and the impact on HIV treatment. DESIGN: Multivariable regression of cross-sectional data from 1163 HIV-infected and 294 controls from the Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). METHODS: An analysis of (1) prevalence of specific illicit drug use (ever, current), (2) being on HAART among those with an indication and (3) current HIV RNA and CD4 cell count among HAART users. RESULTS: Median age was 42 years, approximately 50% were non-Caucasian and 33% were women. Eighty-six percent of HIV-infected and 67% of controls reported ever using illicit drugs (P < 0.0001); 28% of HIV-infected and 16% of controls reported current use (P = 0.0001). In adjusted models, current cocaine use and past heroin use were associated with not currently being on HAART. Among HAART users, those reporting past heroin use were as likely to have an undetectable HIV viral load as those who had never used heroin. Current and past cocaine use and current heroin use was associated with lower odds of undetectable HIV RNA. Past amphetamine use was associated with having an undetectable HIV. Similar results were seen for CD4 lymphocyte counts. CONCLUSION: Illicit drug use in the US is common, although far fewer report current use than past use. Among HIV-infectedpatients, understanding of the type of illicit drugs used and whether drug use was in the past or ongoing is important, because of their differential effects on HIV treatment outcomes.
Authors: W Christopher Mathews; Moira Mar-Tang; Craig Ballard; Brad Colwell; Kari Abulhosn; Craig Noonan; R Edward Barber; Tamara L Wall Journal: AIDS Patient Care STDS Date: 2002-04 Impact factor: 5.078
Authors: Julia H Arnsten; Penelope A Demas; Richard W Grant; Marc N Gourevitch; Homayoon Farzadegan; Andrea A Howard; Ellie E Schoenbaum Journal: J Gen Intern Med Date: 2002-05 Impact factor: 5.128
Authors: Charles H Hinkin; Terry R Barclay; Steven A Castellon; Andrew J Levine; Ramani S Durvasula; Sarah D Marion; Hector F Myers; Douglas Longshore Journal: AIDS Behav Date: 2007-03
Authors: Lynn E Sullivan; Declan Barry; Brent A Moore; Marek C Chawarski; Jeanette M Tetrault; Michael V Pantalon; Patrick G O'Connor; Richard S Schottenfeld; David A Fiellin Journal: Clin Infect Dis Date: 2006-12-15 Impact factor: 9.079
Authors: Evan Wood; Julio S G Montaner; Benita Yip; Mark W Tyndall; Martin T Schechter; Michael V O'Shaughnessy; Robert S Hogg Journal: CMAJ Date: 2003-09-30 Impact factor: 8.262
Authors: Minh Quan Vu; Richard W Steketee; Linda Valleroy; Hillard Weinstock; John Karon; Robert Janssen Journal: J Acquir Immune Defic Syndr Date: 2002-10-01 Impact factor: 3.731
Authors: Joseph A Simonetti; Matthew R Gingo; Lawrence Kingsley; Cathy Kessinger; Lorrie Lucht; Gk Balasubramani; Joseph K Leader; Laurence Huang; Ruth M Greenblatt; John Dermand; Eric C Kleerup; Alison Morris Journal: J AIDS Clin Res Date: 2014-11
Authors: Brent A Moore; Marc I Rosen; Yan Wang; Jie Shen; Karen Ablondi; Anna Sullivan; Mario Guerrero; Lisa Siqueiros; Eric S Daar; Honghu Liu Journal: AIDS Behav Date: 2015-06
Authors: Sarah Finocchario-Kessler; Jacinda K Dariotis; Michael D Sweat; Maria E Trent; Jean M Keller; Quratulain Hafeez; Jean R Anderson Journal: AIDS Patient Care STDS Date: 2010-05 Impact factor: 5.078
Authors: Anthony T Fojo; Catherine R Lesko; Keri L Calkins; Richard D Moore; Mary E McCaul; Heidi E Hutton; William C Mathews; Heidi Crane; Katerina Christopoulos; Karen Cropsey; Michael J Mugavero; Kenneth Mayer; Brian W Pence; Bryan Lau; Geetanjali Chander Journal: AIDS Behav Date: 2019-03
Authors: Wynne Callon; Mary Catherine Beach; Somnath Saha; Geetanjali Chander; Ira B Wilson; Michael Barton Laws; Victoria Sharp; Jonathan Cohn; Richard Moore; P Todd Korthuis Journal: J Gen Intern Med Date: 2016-05-19 Impact factor: 5.128
Authors: Raquel B De Boni; Bryan E Shepherd; Beatriz Grinsztejn; Carina Cesar; Claudia Cortés; Denis Padgett; Eduardo Gotuzzo; Pablo F Belaunzarán-Zamudio; Peter F Rebeiro; Stephany N Duda; Catherine C McGowan Journal: AIDS Behav Date: 2016-11
Authors: E J Edelman; K S Gordon; J P Tate; W C Becker; K Bryant; K Crothers; J R Gaither; C L Gibert; A J Gordon; Bdl Marshall; M C Rodriguez-Barradas; J H Samet; M Skanderson; A C Justice; D A Fiellin Journal: HIV Med Date: 2016-11 Impact factor: 3.180